glp 1 bmi range for GLP-1: what body mass index do you actually need to qualify I did it!! No longer

doi: 10.1161/CIRCULATIONAHA.125.074545 Summary Keywords cardiovascular outcomes, SGLT2 inhibitors, GLP-1 agonists, combination therapy, heart failure, renal outcomes Citation Aristizbal-Colorado D, Corredor-Rengifo D, Sierra-Castillo S, Lpez-Corredor C, Vernaza-Trujillo D-A, Weir-Restrepo D, Izquierdo-Condoy JS, Ortiz-Prado E, Rico-Fontalvo J, Gmez-Mesa J-E, Abreu-Lomba A and Rivera-Martnez W-A (2025) A decade of progress in type 2 diabetes and cardiovascular disease: advances in SGLT2 inhibitors and GLP-1 receptor agonists a comprehensive review

Perceptual characterization of the Macronutrient Picture System (MaPS) for food image fMRI

Rosenstock, J., et al

Every product and company on our website must undergo assessment for: marketing claims good business practices medical credibility company reputation While we partner with some GLP-1 providers, they still need to pass our vetting process

The study did not find similar optic nerve risks with drugs such as Mounjaro or Zepbound, which use a different mechanism

Wegovy (semaglutide) [package insert]